FIELD: pharmaceutics.
SUBSTANCE: present invention proposes a pharmaceutical composition including Janus kinase inhibitor or its pharmaceutically acceptable salt. In particular, present invention proposes a pharmaceutical composition including (3aR,5s,6aS)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl(7Н-pyrollo[2,3-d]pyrimidin-4-yl) amino) hexahydrocyclopenta[с]pyrrol-2(1Н)-carboxamide or its pharmaceutically acceptable salt and cellulose ester.
EFFECT: according to present invention the pharmaceutical composition is characterized by quick dissolution rate and good stability.
5 cl, 3 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BISULFATE OF JANUS KINAZE (JAK) INHIBITOR AND METHOD FOR ITS PREPARATION | 2014 |
|
RU2665680C2 |
| CRYSTALLINE FORM OF INHIBITOR BISULPHATE JAK AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2704795C2 |
| CRYSTALLINE FORM OF BISULPHATE JAK-KINASE INHIBITOR AND A METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2716260C2 |
| DERIVATIVES OF PYRROLOPYRIMIDINE USEFUL AS JAK-KINASES INHIBITORS | 2012 |
|
RU2618673C2 |
| PYRAZOLE-BASED MAGL INHIBITORS | 2018 |
|
RU2789157C2 |
| PHARMACEUTICAL COMPOSITION | 1992 |
|
RU2121835C1 |
| PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION | 2018 |
|
RU2767872C2 |
| PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITOR OF HMG-REDUCTASE | 2000 |
|
RU2206324C1 |
| PHARMACEUTICAL COMBINATIONS | 2014 |
|
RU2684106C2 |
| PHARMACEUTICALLY ACCEPTABLE SOLUBILISING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING IT | 2007 |
|
RU2469708C2 |
